ADVANCED HEALTH LIMITED - Renewal of Cautionary regarding Presmed Australia's investment in DEVOCLEA

Renewal of Cautionary regarding Presmed Australia's investment in DEVOCLEA

 ADVANCED HEALTH LIMITED
 (Incorporated in the Republic of South Africa)
 (Registration number 2013/059246/06)
 (“the Company” or “Advanced Health”)
 ISIN Code: ZAE000189049        JSE Code: AVL


RENEWAL OF CAUTIONARY REGARDING PRESMED AUSTRALIA’S INVESTMENT IN DEVOCLEA


 Renewal of Cautionary announcement
 Shareholders are referred to the detailed terms and cautionary announcement that was released
 on SENS on 11 June 2021 and the update announcements released on 30 June 2021 and 8 July 2021
 regarding Presmed Australia Pty Limited’s (“PMA”), acquisition of a 20% interest in the Devonport
 Eye Hospital (NWC) Pty Ltd (“Devonport Eye Hospital”) and Clearvis Pty Ltd (“Clearvis”) (collectively
 “DEVOCLEA”), (the “Transaction”).

 The financial accounts for the year ending 30 June 2021, from which the additional Transaction
 consideration amount will be determined based on the adjusted EBITDA of DEVOCLEA, are still being
 finalised. In terms of the Share Sale Agreement, once the 30 June 2021 financial accounts are
 finalised, PMA has three months in which to make payment of the additional Transaction
 consideration amount.

 Pending the finalisation and announcement of the additional Transaction consideration amount,
 shareholders are advised to continue to exercise caution when dealing in the company’s securities
 until such further announcement has been released.

Johannesburg
20 August 2021

Designated Advisor
Grindrod Bank Limited

Date: 20-08-2021 12:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.